TxCell, a French biotech working on T cell treatments for chronic inflammatory and autoimmune diseases, says that Belgian CMO MaSTherCell has successfully completed manufacturing validation runs of its lead drug candidate Ovasave. TxCell contracted with the CMO after French authorities last year shut down its own pilot plant in Besançon because of sterility concerns. The company said it has submitted to authorities amendments to its clinical protocol and expects this will allow it to resume its clinical study of Ovasave. Release | More